FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385455811> ?p ?o ?g. }

• W4385455811 abstract "Optimizing vaccine efficacy is of particular concern in patients undergoing hematopoietic stem cell transplantation (HSCT), which mainly have an inadequate immune response to primary SARS-CoV-2 vaccination. This investigation aimed to explore the potential prime-boost COVID-19 vaccination strategies following autologous (auto-) HSCT.In a randomized clinical trial, patients who had already received two primary doses of receptor-binding domain (RBD) tetanus toxoid (TT) conjugated SARS-CoV-2 vaccine during three to nine months after auto-HSCT were randomized to receive either a homologous RBD-TT conjugated or heterologous inactivated booster dose four weeks after the primary vaccination course. The primary outcome was comparing the anti-S IgG Immune status ratio (ISR) four weeks after the heterologous versus homologous booster dose. The assessment of safety and reactogenicity adverse events was considered as the secondary outcome.Sixty-one auto-HSCT recipients were recruited and randomly assigned to receive either homologous or heterologous booster doses four weeks after the primary vaccination course. The mean ISR was 3.40 (95% CI: 2.63- 4.16) before the booster dose with a 90.0% seropositive rate. The ISR raised to 5.12 (95% CI: 4.15- 6.08) with a 100% seropositive rate after heterologous (P= 0.0064) and to 3.42 (95% CI: 2.67- 4.17) with a 93.0% seropositivity after the homologous booster doses (P= 0.96). In addition, the heterologous group suffered more AEs following the booster dosage than the homologous group, but this difference was not statistically significant (p = 0.955). In multivariable analysis, the prime-boost vaccination strategy (heterologous versus homologous), the level of ISR before the booster dose, and the length of time between auto-HSCT and booster dose were the positive predictors of serologic response to a booster dose. No serious adverse event is attributed to booster vaccination.In patients who were primed with two SARS-CoV-2 vaccine doses during the first year after auto-HSCT, heterologous prime-boost COVID-19 vaccination with inactivated platform resulted in considerably enhanced serologic response and non-significantly higher reactogenicity adverse events than homologous RBD-TT conjugated prime-boost COVID-19 vaccination strategy." @default.
• W4385455811 created "2023-08-02" @default.
• W4385455811 creator A5006828182 @default.
• W4385455811 creator A5012837397 @default.
• W4385455811 creator A5013675371 @default.
• W4385455811 creator A5019808123 @default.
• W4385455811 creator A5022453940 @default.
• W4385455811 creator A5066206979 @default.
• W4385455811 creator A5090959902 @default.
• W4385455811 date "2023-08-01" @default.
• W4385455811 modified "2023-09-25" @default.
• W4385455811 title "Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial" @default.
• W4385455811 cites W3122861027 @default.
• W4385455811 cites W3165091170 @default.
• W4385455811 cites W3189762432 @default.
• W4385455811 cites W3205729630 @default.
• W4385455811 cites W3206518950 @default.
• W4385455811 cites W3210126657 @default.
• W4385455811 cites W4200252704 @default.
• W4385455811 cites W4200595269 @default.
• W4385455811 cites W4205275556 @default.
• W4385455811 cites W4205521981 @default.
• W4385455811 cites W4206906464 @default.
• W4385455811 cites W4223913605 @default.
• W4385455811 cites W4225726091 @default.
• W4385455811 cites W4226343533 @default.
• W4385455811 cites W4280541635 @default.
• W4385455811 cites W4281651241 @default.
• W4385455811 cites W4282571509 @default.
• W4385455811 cites W4282975475 @default.
• W4385455811 cites W4292061053 @default.
• W4385455811 cites W4292230050 @default.
• W4385455811 cites W4295488546 @default.
• W4385455811 cites W4313398561 @default.
• W4385455811 cites W4313398643 @default.
• W4385455811 cites W4313494545 @default.
• W4385455811 cites W4318542652 @default.
• W4385455811 cites W4366429903 @default.
• W4385455811 doi "https://doi.org/10.3389/fimmu.2023.1237916" @default.
• W4385455811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37593732" @default.
• W4385455811 hasPublicationYear "2023" @default.
• W4385455811 type Work @default.
• W4385455811 citedByCount "0" @default.
• W4385455811 crossrefType "journal-article" @default.
• W4385455811 hasAuthorship W4385455811A5006828182 @default.
• W4385455811 hasAuthorship W4385455811A5012837397 @default.
• W4385455811 hasAuthorship W4385455811A5013675371 @default.
• W4385455811 hasAuthorship W4385455811A5019808123 @default.
• W4385455811 hasAuthorship W4385455811A5022453940 @default.
• W4385455811 hasAuthorship W4385455811A5066206979 @default.
• W4385455811 hasAuthorship W4385455811A5090959902 @default.
• W4385455811 hasBestOaLocation W43854558111 @default.
• W4385455811 hasConcept C104317684 @default.
• W4385455811 hasConcept C121332964 @default.
• W4385455811 hasConcept C12590561 @default.
• W4385455811 hasConcept C126322002 @default.
• W4385455811 hasConcept C1276947 @default.
• W4385455811 hasConcept C197934379 @default.
• W4385455811 hasConcept C203014093 @default.
• W4385455811 hasConcept C203165030 @default.
• W4385455811 hasConcept C22070199 @default.
• W4385455811 hasConcept C2777351567 @default.
• W4385455811 hasConcept C2777408962 @default.
• W4385455811 hasConcept C2777704310 @default.
• W4385455811 hasConcept C2779841045 @default.
• W4385455811 hasConcept C2780115692 @default.
• W4385455811 hasConcept C2780801004 @default.
• W4385455811 hasConcept C2780868878 @default.
• W4385455811 hasConcept C2911091166 @default.
• W4385455811 hasConcept C55493867 @default.
• W4385455811 hasConcept C71924100 @default.
• W4385455811 hasConcept C86803240 @default.
• W4385455811 hasConcept C8891405 @default.
• W4385455811 hasConceptScore W4385455811C104317684 @default.
• W4385455811 hasConceptScore W4385455811C121332964 @default.
• W4385455811 hasConceptScore W4385455811C12590561 @default.
• W4385455811 hasConceptScore W4385455811C126322002 @default.
• W4385455811 hasConceptScore W4385455811C1276947 @default.
• W4385455811 hasConceptScore W4385455811C197934379 @default.
• W4385455811 hasConceptScore W4385455811C203014093 @default.
• W4385455811 hasConceptScore W4385455811C203165030 @default.
• W4385455811 hasConceptScore W4385455811C22070199 @default.
• W4385455811 hasConceptScore W4385455811C2777351567 @default.
• W4385455811 hasConceptScore W4385455811C2777408962 @default.
• W4385455811 hasConceptScore W4385455811C2777704310 @default.
• W4385455811 hasConceptScore W4385455811C2779841045 @default.
• W4385455811 hasConceptScore W4385455811C2780115692 @default.
• W4385455811 hasConceptScore W4385455811C2780801004 @default.
• W4385455811 hasConceptScore W4385455811C2780868878 @default.
• W4385455811 hasConceptScore W4385455811C2911091166 @default.
• W4385455811 hasConceptScore W4385455811C55493867 @default.
• W4385455811 hasConceptScore W4385455811C71924100 @default.
• W4385455811 hasConceptScore W4385455811C86803240 @default.
• W4385455811 hasConceptScore W4385455811C8891405 @default.
• W4385455811 hasLocation W43854558111 @default.
• W4385455811 hasLocation W43854558112 @default.
• W4385455811 hasOpenAccess W4385455811 @default.
• W4385455811 hasPrimaryLocation W43854558111 @default.
• W4385455811 hasRelatedWork W1975971370 @default.
• W4385455811 hasRelatedWork W1976751856 @default.

• next